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Abstract: The therapeutic applications of gold are well-known for many centuries. The most
used gold compounds contain Au(I). Herein, we report, for the first time, the ability of four
Au(I) and Au(III) complexes, namely dichloro (2-pyridinecarboxylate) Au(III) (abbreviated as 1),
chlorotrimethylphosphine Au(I) (2), 1,3-bis(2,6-diisopropylphenyl) imidazole-2-ylidene Au(I) chloride
(3), and chlorotriphenylphosphine Au(I) (4), to affect the sarcoplasmic reticulum (SR) Ca2+-ATPase
activity. The tested gold compounds strongly inhibit the Ca2+-ATPase activity with different effects,
being Au(I) compounds 2 and 4 the strongest, with half maximal inhibitory concentration (IC50)
values of 0.8 and 0.9 µM, respectively. For Au(III) compound 1 and Au(I) compound 3, higher IC50
values are found (4.5 µM and 16.3 µM, respectively). The type of enzymatic inhibition is also different,
with gold compounds 1 and 2 showing a non-competitive inhibition regarding the native substrate
MgATP, whereas for Au compounds 3 and 4, a mixed type of inhibition is observed. Our data
reveal, for the first time, Au(I) compounds with powerful inhibitory capacity towards SR Ca2+ATPase
function. These results also show, unprecedently, that Au (III) and Au(I) compounds can act as P-type
ATPase inhibitors, unveiling a potential application of these complexes.
Keywords: Gold(I, III) compounds; Ca2+-ATPase; P-type ATPases inhibitors; anticancer
1. Introduction
Gold compounds were used in medicine in ancient Egypt, Arabia, India, and China [1]. Later on,
in Europe, Paracelsus (1493–1541) described the preparation of red colloidal gold by reduction of
gold trichloride with an alcoholic extract of plants, followed by the addition of sugar or syrup.
This preparation was named aurum potable, quinta essential auri, or oleum auri, being used in the
treatment of several diseases (such as syphilis), for improving strength, prolonging life and rejuvenating.
In 1618, Francisco Antonii published the first book on colloidal gold, which was preserved until
nowadays. It contains information on the preparation of gold colloids and on its medical applications,
including practical suggestions. In 1927, colloidal gold started to be used in rheumatoid arthritis (RA),
and in 2013, Au(III) compounds were reported for the first time as Na+/K+-ATPase inhibitors [2,3].
Other medical applications of colloidal gold are described elsewhere [4].
Later, the well-known orally active Au(I)-phosphine-thiolate, a dicoordinate complex, also named
auranofin, was developed to treat RA in clinical tests [2,5,6]. Aurothiomalate, aurothioglucose,
and auro-bis(thiosulfate) are drugs with composition and structure similar to auranofin that have been
extensively referred as anticancer agents [7–13].
The ligands present on gold complexes are also a subject of design. In recent years,
anti-cancer-active Au(I) complexes containing multidentate N-donor ligands (e.g., 2,2′-terpyridine;
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6′,2′′-terpyridine, 2,2′-bipyridine, porphyrin), cyclometalating or dithiocarbamate ligands were
reported [14]. Gold(I) complexes containing phosphine, N-heterocyclic carbene (NHC), thiolate,
alkynyl, thiourea, triazole-peptide or other ligands were also studied for the same purpose [15].
Additionally, gold compounds have been a subject of research in terms of antibacterial, antivirus and
anti-parasite activity [12,13,16,17] and in Alzheimer’s disease [18]. Gold compounds, together with
vanadium complexes and polyoxometalates, have been selected by some researchers as alternative
anti-tumor substances with promising results in tumor growth suppression [19–23]. Moreover, some of
these studies used gold nanoparticles functionalized with polyoxometalates, which are highly uptaken
by cancerous cells [13].
Although the biological effects of gold compounds, either Au(I) or Au(III), are known,
their molecular mechanisms are largely unknown. It is possible to define three major classes
according to their mode of action towards biological targets: (1) Involving an alkylation mechanism:
Coordination to biomolecules side chains, e.g., thiols, imidazole and selenols, after activation (gold
compounds are prodrugs), through the release of labile ligands; e.g., auranofin; (2) As DNA
intercalators: Gold complexes are capable of crossing membranes and binding noncovalently to
proteins, enzymes, DNA, some examples being gold(III) porphyrins; (3) In redox reactions with
biomolecules causing oxidative damage, e.g., Auoxo6 [24]. Moreover, the antitumor activity of
these inorganic compounds is also attributed, at least in part, to the inhibition of certain protein
functions, for example aquaporin [22,23], P-type ATPases [3] and protein tyrosine phosphatases, among
others [7–13]. Some of them, like Na+/K+-ATPase and Ca2+-ATPase, are putative pharmacological
targets of a substantial number of drugs, well-known as ion pumps inhibitors [25–28]. To the best of
our knowledge, only a few studies describe the use of gold compounds as Na+/K+-ATPase inhibitors
(including [3,29]).
In this work, we describe and compare, for the first time, the effects of both gold(I) and gold(III)
compounds in P-type ATPases, particularly in Ca2+-ATPase function. The compounds used are shown
in Figure 1, dichloro (2-pyridinecarboxylate) gold (1) being the only gold(III) compound, the other
three are gold(I) complexes. They were successfully used as catalysts in the oxidation of alkanes and
alcohols in a previous work [30].
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Figure 1. Gold complexes (1) dichloro (2-pyridinecarboxylate) gold(III); (2) chlorotrimethylphosphine
gold(I); (3) 1,3-bis(2,6-diisopropylphenyl) imidazole-2-ylidene gold(I) chloride and (4)
chlorotriphenylphosphine gold(I), showing the formal charge distribution.
The aims of the present study are: (i) to test the extent of Ca2+-ATPase inhibition of gold complexes
1–4; (ii) to characterize the type of Ca2+-ATPase inhibition regarding the protein native substrate
MgATP; (iii) to compare the inhibition capacity of the gold complexes with other metal compounds
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and with well-known drugs that target P-type ATPases; (iv) to obtain a more accurate description of
the targets involved in the mechanism of action of gold complexes and their possible biological effects.
2. Results
Inhibition of Ca2+-ATPase by Gold Compounds
The effects of four gold compounds on the activity of the sarcoplasmic reticulum (SR) Ca2+-ATPase
was investigated for the first time (results shown in Figures 2 and 3). Compounds were added to the
assay just a few seconds before the beginning of the experiment and the reaction time was 3 min. All the
Au complexes inhibited Ca2+-ATPase activity, which is expressed as percentage of the control enzyme
value obtained without inhibitor, in a concentration dependent manner. The inhibitory capacity of
the investigated gold compounds was evaluated by the half maximal inhibitory concentration (IC50)
values, meaning that the inhibitor concentration induced 50% of Ca2+-ATPase inhibition of the enzyme
activity. The IC50 values ranged from 0.8 to 16.3 µM. Gold(I) compounds 2 and 4 showed the lowest
IC50 values: 0.8 and 0.9 µM, respectively, indicating a higher inhibition (Figure 2A,B). The gold(III)
compound 1 and gold(I) compound 3 exhibited IC50 values in the range of 4–16 µM (Figure 3A,B).
Thus, the Au(I) complexes 2 and 4 were, respectively, around 6–20 fold more powerful inhibitors of the
ATPase than compounds 1 and 3 (Table 1).
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Table 1. Km, Vmax and IC50 values of Ca2+-ATPase inhibition by gold compounds.
Gold Compound Km (mM)
Vmax
(nM ATP·min−1) Type of Inhibition IC50 (µM)
1
0 (µM) 0.243 ± 0.024 a 67.57 ± 8.85 a
non-competitive 4.5 ± 0.1 a
4 (µM) 0.255 ± 0.019 a 30.77 ± 5.34 b
2
0 (µM) 0.098 ± 0.011 b 51.55 ± 4.38 c
non-competitive 0.8 ± 0.1 b
1 (µM) 0.096 ± 0.012 b 41.67 ± 3.31 d
3
0 (µM) 0.257 ± 0.021 a 75.76 ± 6.87 e
mixed 16.3 ± 0.1 c
15 (µM) 0.421 ± 0.025 c 60.98 ± 2.98 f
4
0 (µM) 0.210 ± 0.016 d 42.02 ± 2.78 d
mixed 0.9 ± 0.1 b
1 (µM) 0.281 ± 0.020 e 22.62 ± 2.08 g
a–d Averages with different letters in same column are significantly different (p < 0.05).
It is worth noting that the presence of gold compounds, under the conditions used in the enzymatic
assays, does not affect the basal activity of the ATPase (see Material and Methods section). This means
that, for the concentrations used in the experiments, the gold compounds do not induce uncoupling of
the process. This also means that vesicles containing the ATPase maintain their integrity, thus ATP
hydrolysis and calcium transport are coupled, and the inhibitory capacity can be evaluated after the
addition of the ionophore.
Using concentrations near the IC50 values displayed in Table 1, the type of inhibition of the four
gold compounds was analyzed, regarding the native substrate of the ATPase, MgATP. It was observed
that both Au(III) compound 1 and also Au(I) compound 2 present a non-competitive type of inhibition
(Table 1, Figure 4A,B). It can be seen that the values of Km obtained with complexes 1 and 2 are very
similar to those observed for the control (in the absence of compounds), whereas Vmax values decreased
(Table 1, Figure 4). On the other hand, it can be observed that both Au(I) compounds 3 and 4 present a
mixed type inhibition, once their Vmax values decrease, compared to the control, whereas Km values
increase (Table 1, Figure 5A,B). Thus, it can be suggested that both Au(I) compounds 3 and 4 can
interact with Ca2+-ATPase, whether or not the enzyme has already bound to the substrate, pointing
out two distinct protein binding sites for these complexes.
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Figure 5. Lineweaver-Burk plots of Ca2+-ATPase activity in the absence (blue) and in the presence
(orange) of 1 or 15 µM of the gold compounds (A) Gold compound 3; (B) Gold compound 4. The plots
were used for determining the type of enzyme inhibition. The gold complexes presented a mixed
type of inhibition. Data are plotted as means ± SD. The results shown are the average of triplicate
experiments carried out in distinct preparations.
Moreover, compounds were incubated for 30 min with and without the protein and the inhibitory
effects of the ATPase were the same as without any incubation, suggesting that the Au compounds are
stable, and the effects observed can be attributed their addition to the medium.
3. Discussio
We studied the effects of the four gold compounds mentioned above (Figure 1, Table 2 of Materials
and Methods section) on the activity of sarcoplasmic reticulum (SR) Ca2+-ATPase. It is worth noting
that the gold compounds solutions prepared in DMSO are colorless and the UV-Vis spectra obtained
after 1 min is the same as the measured after 30 min, showing their stability.
Table 2. Gold compounds used in the present study (structures can be found in Figure 1).
Formula Abbreviation Net Charge MW (g/mol) CAS Number
C6H4NAuCl2O2 1 +3 389.97 88215-41-2
C3H9PAuCl 2 +1 308.50 15278-97-4
C27H36AuClN2 3 +1 621.01 852445-83-1
C18H15PAuCl 4 +1 494.71 14243-64-2
Gold(I) compounds 2 and 4 strongly inhibit Ca2+-ATPase, showing IC50 values of 0.8 and 0.9 µM.
Using exactly the same experimental conditions as those of the present study, similar Ca2+-ATPase
IC50 values of inhibition were previously determined for polyoxotungstates (POTs), such as P2W18
(0.6 µM) and for Se2W29 (IC50 = 0.3 µM), as well as for polyoxovanadates (POVs), such as PV14
(IC50 = 1 µM) [31,32]. However, a lower capacity was observed for some POTs, such as TeW6
(IC50 = 200 µM) [31]. Inhibitory power (IC50) ranging from 1 to 35 µM was reported for decaniobate
[Nb10O28]6− (IC50 = 35 µM) and for Keggin-based polyoxotungstates (POTs), such as mono-substituted
CoW11 (IC50 = 4 µM), tri-lacunary SiW9 (IC50 = 16 µM) and AsW9 (20 µM), lacunary Dawson type
P2W12 (11 µM), and also for As2W19 (28 µM) [31]. Note that the P-type TPases have long been
known to be inhibited by metal complexes although the structural details of its inhibitory mechanism
remain unresolved [27,29,31–35]. Regarding the Ca2+-ATPase, it was previously determined that
polyoxova adates, such as decavanadate (V10) (IC50 = 15 µM), are more powerful Ca2+-ATPase
inhibit rs than monomeric vanadate (V1) (IC50 = 80 µM). Herein, we show that gol (I) compounds
2 and 4 ar stronger inhibitors of the ca cium pump (IC50 < 1 µM), whereas gold(III) compound 1
and gold(I) compound 3, although with less capacity, can be also considered as complexes with high
affinity for the ATPase (IC50 < 16 µM).
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Both decaniobate (Nb10) and decavanadate (V10) showed to be Ca2+-ATPase non-competitive
inhibitors regarding the natural ligand MgATP [34]. The same type of inhibition (non-competitive)
was observed in this work for gold(III) compound 1 and gold(I) compound 2, as they did not bind to
ATP binding site. On the other hand, the gold(I) compounds 3 and 4 presented a mixed type inhibition,
as previously observed for POTs and POVs, such as P2W18 and PV14 [31,32]. This observation suggests
that these gold(I) compounds can interact with the Ca2+-ATPase, whether or not the enzyme has
already bound substrate, and point out to the existence of two distinct protein binding sites for these
types of gold compounds, one of them probably being the ATP binding site.
The non-competitive type of inhibition observed for gold compounds 1–4 is in agreement with
previous studies dealing with Na+/K+-ATPase. For example, it was previously described that gold(III)
complexes H[AuCl4], [Au(DMSO)2Cl2]Cl, and [Au(bipy)Cl2]Cl (bipy = 2,2′-bipyridine), inhibited the
enzymatic activity of a commercially available Na+/K+-ATPase, with IC50 values of, respectively, 0.7,
5.5, and 39.8 µM [3]. It was also reported that this inhibition can be prevented using –SH donating
ligands, such as L-Cys and glutathione. Moreover, a non-competitive mode of the interaction was
referred for all compounds [3]. In contrast to Au salts, no ionic Au is present in solution when those
complexes are used. Those organic gold compounds tend to undergo ligand exchange reactions
with protein thiols, which may be responsible for the inhibitory properties. In our study, the gold(I)
compound 2 (that presents higher inhibitory potential for the Ca2+-ATPase) showed a non-competitive
type of inhibition, suggesting that it does not bind to the ATP binding site. However, gold(I) compound
4, showed a similar inhibitory potential, but with a mixed type of inhibition.
It is worth mentioning that within a physiological pH range (required for optimal activity of
Ca2+-ATPases and in the majority of biological investigations), the gold compounds are not expected
to undergo partial hydrolysis as it occurs for instance with polyoxometalates studies, where the
chemical species inducing the effects should be ascertain [36]. However, in the experiments referred
to above, dealing with the determination of the type of inhibition and IC50 values, it was observed
that the incubation of the gold(I) or gold(III) compounds in the medium did not affect the inhibition
of the enzyme, suggesting that the compounds are stable under the experimental conditions used.
Still, although further investigations are needed, it can be assumed that the intact gold compounds are
responsible for the effects observed in the Ca2+-ATPase, as already referred.
It was suggested by Bondžić et al. that gold(III) compounds, i.e., [Au(bipy)(OH)2][PF6],
bipy = 2,2′-bipyridine; [Au(pydmb-H)(CH3COO)2], pydmb-H = deprotonated 6-(1,1-dimethylbenzyl)-
pyridine and [Au(bipydmb-H)(OH)][PF6], bipyc-H = deprotonated 6-(1,1-dimethylbenzyl)-2,2′-bipyridine,
can bind to the E1 conformation of the Na+/K+-ATPase [29]. The different binding modes of these gold(III)
complexes to the enzyme were explained based on their distinctive structural features. In contrast to
gold(III), vanadate only binds to the E2 conformation of the Ca2+-ATPase (another P-type ATPase),
whereas decavanadate (V10) strongly binds to either E1 or E2 conformations, being phosphorylated or
not [34]. However, to the majority of the inorganic compounds, the protein conformations and binding
sites are still to be determined [33,34]. For some drugs, such as thapsigargin (TG) and cyclopiazonic acid
(CPA), the mechanisms of action and ATPases binding sites are clearly established [28].
In fact, several drugs are known as ionic pump inhibitors, such as ouabain, omeprazole or
thapsigargin. For the Ca2+-ATPase, TG (IC50 = 0.001–0.029 µM), CPA (IC50 = 0.1–0.2 µM), macrocyclic
lactones (IC50 = 66–72 µM), curcuminoides (IC50 = 7–17 µM) and celecoxib (IC50 = 35 µM) are examples
of well-known inhibitors [37–41]. These organic inhibitors of the Ca2+-ATPases, are used for several
disease treatments, such as heart failure, psychosis, malaria and also as anaesthetics, tumour inhibitors,
antibiotics and insulin mimetic agents [37–41], presenting inhibitory capacity not so different from
the gold compounds described in the present study. Herein, we aimed to compare the inhibitory
capacity of complexes 1–4 with oxometalates, metal complexes, polyoxometalates (POTs and POVs),
and distinguish between gold(I) and gold(III) compounds (IC50 = 0.8–16.3 µM). Thus, it was described
that several inorganic compounds and complexes present Ca2+-ATPases IC50 inhibition values globally
not so different from the above well-known Ca2+-ATPases drugs inhibitors, for example decavanadate
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(IC50 = 15 µM), polyoxotungstates (IC50 = 0.3–200 µM), polyoxovanadates (IC50 =1 µM), and vanadium
complexes such as BMOV (IC50 = 40 µM), among others [31–35]. In summary, both gold(I) and gold(III)
compounds 1–4 are strong inhibitors of the SR Ca2+-ATPase, pointing out this enzyme as a putative
target for gold compounds with anticancer activity, described as promising agents for the future in
medicinal chemistry [1–18,23,29,42–44].
4. Materials and Methods
4.1. Gold Compounds
Au(I) and Au(III) complexes were used (Table 2). Their chemical structures can be found in Figure 1.
Dichloro(2-pyridinecarboxylate)gold(III) (1) was purchased from Aldrich. The Au(I) complexes
chlorotrimethylphosphinegold(I) (2), 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidenegold(I) chloride
(3) and chlorotriphenylphosphinegold(I) (4) (Figure 1, Table 2), were purchased from Strem Chemicals
(Newburyport, MS, USA).
Stock solutions of the gold complexes (10 mM) were freshly prepared by dissolving the solid
compounds in dimethyl sulfoxide (DMSO) and keeping the solution at room temperature before use.
Wherever adequate, the freshly prepared solutions were diluted to 1 and/or 0.1 mM final concentrations
before use in the enzymatic assays.
4.2. Preparation of Sarcoplasmic Reticulum Ca2−ATPase Vesicles
Sarcoplasmic reticulum (SR) Ca2+-ATPase-1 (SERCA-1) was prepared from rabbit skeletal muscles
as described elsewhere [34]. The vesicles were suspended in 0.1 M KCl, 10 mM HEPES (pH 7.0),
diluted 1:1 with 2.0 M sucrose and frozen in liquid nitrogen for storage at −80 ◦C. As analyzed by
SDS-PAGE (Bio-Rad Laboratories, Inc., Hercules, CA, USA), Ca2+-ATPase constituted at least 70% of
the total protein.
4.3. Effects of Gold Compounds in the ATP Hydrolysis by the SR Ca2+-ATPase
Ca2+-ATPase activities were measured spectrophotometrically (Shimadzu, UV 2401-PC, Shimadzu
Corporation, Kyoto, Japan) at 22 ◦C, using the coupled enzyme pyruvate kinase/lactate dehydrogenase
assay, as described elsewhere [21,31,32,34,35]. The reaction medium contained: 25 mM HEPES (pH 7.0),
100 mM KCl, 5 mM MgCl2, 50 µM CaCl2, and 2.5 mM ATP. For the coupled enzyme assay 0.42 mM
phosphoenolpyruvate, 0.25 mM NADH, 18 IU lactate dehydrogenase and 7.5 IU pyruvate kinase were
added to the medium. The experiments were initiated by the addition of 10 µg/mL calcium ATPase,
and the absorbance at 340 nm was recorded during about 1 min (basal activity). Without stopping the
reaction, 4% (w/w) of calcium ionophore A23187 were added to the cuvette and the enzyme kinetics of
ATP hydrolysis was followed for more 2 min. Wherever adequate, freshly prepared gold compounds
solutions were added to the medium immediately prior to Ca2+-ATPase addition. Finally, the ATPase
activities were measured, taken into consideration the slope of the decrease of the absorbance (at 340 nm)
per minute, in the absence (100%) or in the presence of the inhibitor. All experiments were performed at
least in triplicate. The inhibitory power of the investigated gold compounds was evaluated determining
IC50 values, meaning the gold compound concentration inducing 50% inhibition of Ca2+-ATPase
enzyme activity. The IC50 values were determined according to the equations shown in the graphics
obtained after the best fitting of the experimental points.
4.4. Statistical Analysis
Calculations of IC50 were performed using Microsoft Office 365 Excel (2019) (Microsoft, Redmond,
WA, USA). All values shown are presented as averages and standard deviations of measurements
taken from triplicate measurements, using three distinct and independent Ca2+-ATPase preparations.
The statistical significance of the data was assessed using the Student’s t-test. Differences from controls
were considered significant, at p < 0.05.
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5. Conclusions
Sarcoplasmic reticulum Ca2+-ATPase activity was inhibited by both Au(I) or Au(III) compounds.
Particularly significant inhibition values were found for the Au(I) compounds 2 and 4 (IC50 < 1 µM),
similar to those previously described for POTs. A non-competitive type of inhibition was found for
the smaller gold(I) compound 2, which was the most powerful ATPase inhibitor, even superior to the
well-known inorganic P-type ATPase non-competitive inhibitors, such as decavanadate (IC50 = 15 µM).
A similar inhibiting potential, but with a mixed type of inhibition, was found for gold(I) compound
4, suggesting that the different complexes have different modes of interaction with the Ca2+-ATPase,
however maintaining the high affinity for the enzyme. Although more investigations are needed
to establish structure-activity relationships, both Au(I) or Au(III) compounds can be considered
as responsible for the observed Ca2+-ATPase inhibitory effect, showing good inhibitory capacity,
suggesting this enzyme to be a potential gold target for future medicinal inorganic chemistry (Figure 6).
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